Literature DB >> 33389113

Concordance of laparoscopic and laparotomic peritoneal cancer index using a two-step surgical protocol to select patients for cytoreductive surgery in advanced ovarian cancer.

Martina Aida Angeles1, Federico Migliorelli2, Mathilde Del1, Carlos Martínez-Gómez1,3, Manon Daix1, Sarah Bétrian4, Erwan Gabiache5, Gisèle Balagué6, Sophie Leclerc7, Eliane Mery8, Laurence Gladieff4, Gwénaël Ferron1,9, Alejandra Martinez10,11.   

Abstract

PURPOSE: The aim of our study was to assess concordance of staging laparoscopy and cytoreductive surgery (CRS) peritoneal cancer index (PCI) when applying a two-step surgical protocol. We also aimed to evaluate the accuracy of diagnostic laparoscopy to triage patients for complete cytoreduction, and to define optimal time between staging laparoscopy and CRS.
METHODS: We designed a retrospective review of prospectively collected data from patients with advanced ovarian cancer who underwent a diagnostic laparoscopy followed by a CRS a few weeks later (two-step surgical protocol), from January 2010 to April 2019. Only patients selected for complete cytoreduction, and with available PCI score from both surgeries were included. PCI concordance was assessed using intraclass correlation coefficient (ICC).
RESULTS: During the study period 543 patients underwent a laparoscopic staging for ovarian carcinomatosis. Among them, 43 patients fulfilled inclusion criteria. ICC between laparoscopic and laparotomic PCI was 0.54. After applying the linear regression equation: laparoscopic PCI + 0.2 x [days between surgeries] + 2, ICC increased to 0.79. Completeness cytoreduction score and laparoscopic PCI were significantly associated (OR 1.27, 95% CI 1.03-1.57, p = 0.03). AUC of laparoscopic PCI to predict complete cytoreduction was 0.90.
CONCLUSION: Concordance between laparoscopic PCI assessment and PCI score at the end of CRS is fair within a two-step surgical management. Laparoscopic assessment underestimates final PCI score by two points, and this difference increases with the delay between both surgeries. Diagnostic laparoscopy can adequately select patients for CRS, and optimal time to perform it is no more than 10 days after laparoscopy.

Entities:  

Keywords:  Advanced ovarian cancer; Complete cytoreduction; Laparoscopic staging; Peritoneal carcinomatosis; Resectability; Sugarbaker index

Mesh:

Year:  2021        PMID: 33389113     DOI: 10.1007/s00404-020-05874-y

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  24 in total

Review 1.  Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.

Authors:  Natalia Rodriguez Gómez-Hidalgo; Bertha Alejandra Martinez-Cannon; Alpa M Nick; Karen H Lu; Anil K Sood; Robert L Coleman; Pedro T Ramirez
Journal:  Gynecol Oncol       Date:  2015-03-28       Impact factor: 5.482

2.  What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

Authors:  D S Chi; E L Eisenhauer; J Lang; J Huh; L Haddad; N R Abu-Rustum; Y Sonoda; D A Levine; M Hensley; R R Barakat
Journal:  Gynecol Oncol       Date:  2006-05-22       Impact factor: 5.482

3.  Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

Authors:  Robert E Bristow; Rafael S Tomacruz; Deborah K Armstrong; Edward L Trimble; F J Montz
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

4.  Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial.

Authors:  Marianne J Rutten; Hannah S van Meurs; Roelien van de Vrie; Katja N Gaarenstroom; Christiana A Naaktgeboren; Toon van Gorp; Henk G Ter Brugge; Ward Hofhuis; Henk W R Schreuder; Henriette J G Arts; Petra L M Zusterzeel; Johanna M A Pijnenborg; Maarten van Haaften; Guus Fons; Mirjam J A Engelen; Erik A Boss; M Caroline Vos; Kees G Gerestein; Eltjo M J Schutter; Brent C Opmeer; Anje M Spijkerboer; Patrick M M Bossuyt; Ben Willem Mol; Gemma G Kenter; Marrije R Buist
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

Review 5.  Quantitative prognostic indices in peritoneal carcinomatosis.

Authors:  F N Gilly; E Cotte; C Brigand; O Monneuse; A C Beaujard; G Freyer; O Glehen
Journal:  Eur J Surg Oncol       Date:  2006-04-17       Impact factor: 4.424

6.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Authors:  Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen
Journal:  J Clin Oncol       Date:  2003-07-14       Impact factor: 44.544

7.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  Gynecol Oncol       Date:  2016-08-08       Impact factor: 5.482

8.  Accuracy and reproducibility of the peritoneal cancer index in advanced ovarian cancer during laparoscopy and laparotomy.

Authors:  Sébastien Gouy; Jérémie Belghiti; Catherine Uzan; Geoffroy Canlorbe; Tristan Gauthier; Philippe Morice
Journal:  Int J Gynecol Cancer       Date:  2013-11       Impact factor: 3.437

9.  Peritonectomy procedures.

Authors:  P H Sugarbaker
Journal:  Ann Surg       Date:  1995-01       Impact factor: 12.969

10.  Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy.

Authors:  Jean-Luc Brun; Roman Rouzier; Frédéric Selle; Sidney Houry; Serge Uzan; Emile Daraï
Journal:  BMC Cancer       Date:  2009-06-06       Impact factor: 4.430

View more
  2 in total

1.  Feasibility of a Multimodal Prehabilitation Programme in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer: A Pilot Study.

Authors:  Berta Diaz-Feijoo; Nuria Agusti-Garcia; Raquel Sebio; Antonio López-Hernández; Marina Sisó; Ariel Glickman; Nuria Carreras-Dieguez; Pere Fuste; Tiermes Marina; Judit Martínez-Egea; Laura Aguilera; Juan Perdomo; Amaia Pelaez; Manuel López-Baamonde; Ricard Navarro-Ripoll; Elena Gimeno; Betina Campero; Aureli Torné; Graciela Martinez-Palli; María J Arguis
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

2.  The importance of the Peritoneal Cancer Index (PCI) to predict surgical outcome after neoadjuvant chemotherapy in advanced ovarian cancer.

Authors:  Friederike Luise Rawert; Veronica Luengas-Würzinger; Sabrina Claßen-Gräfin von Spee; Saher Baransi; Esther Schuler; Katharina Carrizo; Anca Dizdar; Peter Mallmann; Björn Lampe
Journal:  Arch Gynecol Obstet       Date:  2022-03-31       Impact factor: 2.493

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.